Trial of TG4023 Combined With Flucytosine in Liver Tumors
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
This trial is a phase I, open-label, dose-escalating study of the safety or percutaneous intra-tumoral injection of TG4023 (MVA-FCU1) combined with systemic administration of 5-fluorocytosine in patients with primary or secondary hepatic tumors.
创建时间：
2009-09-15
